Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

EQS-News: ENCAVIS AG reaches ready-to-build (RTB) status for a 105 MW solar park in Mecklenburg-Western Pomerania: https://upload.wikimedia.org/wikipedia/commons/thumb/4/44/Encavis_logo.svg/1024px-Encavis_logo.svg.png
EQS-News: ENCAVIS AG reaches ready-to-build (RTB) status for a 105 MW solar park in Mecklenburg-Western Pomerania
EQS-News: ENCAVIS AG reaches ready-to-build (RTB) status for a 105 MW solar park in Mecklenburg-Western Pomerania
EQS-News: SHOP APOTHEKE EUROPE 2022: RECORD SALES OF EUR 1.2 BILLION AND SIGNIFICANTLY IMPROVED MARGINS IN THE SECOND HALF OF THE YEAR.: https://upload.wikimedia.org/wikipedia/commons/thumb/0/07/Shop_Apotheke_Europe_logo.svg/640px-Shop_Apotheke_Europe_logo.svg.png
EQS-News: SHOP APOTHEKE EUROPE 2022: RECORD SALES OF EUR 1.2 BILLION AND SIGNIFICANTLY IMPROVED MARGINS IN THE SECOND HALF OF THE YEAR.
EQS-News: SHOP APOTHEKE EUROPE 2022: RECORD SALES OF EUR 1.2 BILLION AND SIGNIFICANTLY IMPROVED MARGINS IN THE SECOND HALF OF THE YEAR.
Acadia Healthcare Breaks Ground on New Behavioral Health Hospital in Arizona: https://mms.businesswire.com/media/20230306005668/en/1731758/5/ACHCAgave_BH_Groundbreaking_3.6.2023.jpg
Acadia Healthcare Breaks Ground on New Behavioral Health Hospital in Arizona


Acadia Healthcare Company today held a groundbreaking ceremony marking the beginning of construction on the new hospital that the company is building to serve residents of Mesa, Arizona, and

EQS-News: CEO Stefan Feltens to Retire from SHOP APOTHEKE EUROPE.: https://upload.wikimedia.org/wikipedia/commons/thumb/0/07/Shop_Apotheke_Europe_logo.svg/640px-Shop_Apotheke_Europe_logo.svg.png
EQS-News: CEO Stefan Feltens to Retire from SHOP APOTHEKE EUROPE.
EQS-News: CEO Stefan Feltens to Retire from SHOP APOTHEKE EUROPE.
EQS-Adhoc: SHOP APOTHEKE EUROPE N.V.: No prolongation of his term as CEO by Stefan Feltens: https://upload.wikimedia.org/wikipedia/commons/thumb/0/07/Shop_Apotheke_Europe_logo.svg/640px-Shop_Apotheke_Europe_logo.svg.png
EQS-Adhoc: SHOP APOTHEKE EUROPE N.V.: No prolongation of his term as CEO by Stefan Feltens
EQS-Adhoc: SHOP APOTHEKE EUROPE N.V.: No prolongation of his term as CEO by Stefan Feltens
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: Aurubis AG: Aurubis links factoring to sustainability criteria: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23699/Aurubis-Logo.svg.png
EQS-News: Aurubis AG: Aurubis links factoring to sustainability criteria
EQS-News: Aurubis AG: Aurubis links factoring to sustainability criteria
EQS-News: Schaeffler AG: Acquisition of ECO-Adapt SAS strengthens Schaeffler’s portfolio of Lifetime Solutions: https://upload.wikimedia.org/wikipedia/commons/thumb/7/72/Schaeffler_logo.svg/640px-Schaeffler_logo.svg.png
EQS-News: Schaeffler AG: Acquisition of ECO-Adapt SAS strengthens Schaeffler’s portfolio of Lifetime Solutions
EQS-News: Schaeffler AG: Acquisition of ECO-Adapt SAS strengthens Schaeffler’s portfolio of Lifetime Solutions
EQS-News: Nagarro estimates 2022 revenue grew 48.0% over 2021 in constant currency, reiterates 2023 guidance: https://upload.wikimedia.org/wikipedia/commons/0/0a/Nagarro_Horizontal_Light_400x100px_300dpi.png
EQS-News: Nagarro estimates 2022 revenue grew 48.0% over 2021 in constant currency, reiterates 2023 guidance
EQS-News: Nagarro estimates 2022 revenue grew 48.0% over 2021 in constant currency, reiterates 2023 guidance
EQS-News: Nagarro estimates 2022 revenue grew 48.0% over 2021 in constant currency, reiterates 2023 guidance: https://upload.wikimedia.org/wikipedia/commons/0/0a/Nagarro_Horizontal_Light_400x100px_300dpi.png
EQS-News: Nagarro estimates 2022 revenue grew 48.0% over 2021 in constant currency, reiterates 2023 guidance
EQS-News: Nagarro estimates 2022 revenue grew 48.0% over 2021 in constant currency, reiterates 2023 guidance
EQS-News: GRENKE invests in expanding digitalisation, presents preliminary results for 2022 financial year and publishes outlook for 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24105/Grenke_Logo.jpg
EQS-News: GRENKE invests in expanding digitalisation, presents preliminary results for 2022 financial year and publishes outlook for 2023
EQS-News: GRENKE invests in expanding digitalisation, presents preliminary results for 2022 financial year and publishes outlook for 2023
EQS-Adhoc: GRENKE invests in expanding digitalisation, presents preliminary results for 2022 financial year and publishes outlook for 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24105/Grenke_Logo.jpg
EQS-Adhoc: GRENKE invests in expanding digitalisation, presents preliminary results for 2022 financial year and publishes outlook for 2023
EQS-Adhoc: GRENKE invests in expanding digitalisation, presents preliminary results for 2022 financial year and publishes outlook for 2023
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
EQS-News: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
EQS-News: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
EQS-News: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
EQS-Adhoc: Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
EQS-Adhoc: Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
EQS-Adhoc: Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
EQS-Adhoc: Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
EQS-News: KION Group Achieves High Order Intake and Increase in Revenue in 2022, Significant Decline in Earnings: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23724/Kion_Group_logo.svg.png
EQS-News: KION Group Achieves High Order Intake and Increase in Revenue in 2022, Significant Decline in Earnings
EQS-News: KION Group Achieves High Order Intake and Increase in Revenue in 2022, Significant Decline in Earnings
EQS-News: Nagarro SE expands footprint and SAP capabilities with acquisition of MBIS: https://upload.wikimedia.org/wikipedia/commons/0/0a/Nagarro_Horizontal_Light_400x100px_300dpi.png
EQS-News: Nagarro SE expands footprint and SAP capabilities with acquisition of MBIS
EQS-News: Nagarro SE expands footprint and SAP capabilities with acquisition of MBIS
EQS-News: Nagarro SE expands footprint and SAP capabilities with acquisition of MBIS: https://upload.wikimedia.org/wikipedia/commons/0/0a/Nagarro_Horizontal_Light_400x100px_300dpi.png
EQS-News: Nagarro SE expands footprint and SAP capabilities with acquisition of MBIS
EQS-News: Nagarro SE expands footprint and SAP capabilities with acquisition of MBIS
EQS-News: United Internet acquires 13.9 million treasury shares during its public share buyback offer: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24075/330px-UnitedInternet_logo.svg.png
EQS-News: United Internet acquires 13.9 million treasury shares during its public share buyback offer
EQS-News: United Internet acquires 13.9 million treasury shares during its public share buyback offer
EQS-News: United Internet acquires 13.9 million treasury shares during its public share buyback offer: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24075/330px-UnitedInternet_logo.svg.png
EQS-News: United Internet acquires 13.9 million treasury shares during its public share buyback offer
EQS-News: United Internet acquires 13.9 million treasury shares during its public share buyback offer
Athleta Partners with 11 Elite Athletes to Continue its Mission of Empowering Women and Girls: https://mms.businesswire.com/media/20230301005144/en/1725841/5/Power_of_She_Collective_Photo.jpg
Athleta Partners with 11 Elite Athletes to Continue its Mission of Empowering Women and Girls


Today, in honor of Women's History Month and the upcoming International Women's Day, Athleta announced a new, dynamic community of inspirational brand partners who are both accomplished athletes

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc